These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38922297)

  • 1. Development of GPC3-CAR-NK cells and optimization as a therapy for HCC.
    Cao B; Ni Q; Chen Z; Yang S; Zhang X; Su H; Zhang Z; Zhao Q; Zhu X; Liu M
    J Leukoc Biol; 2024 Jun; ():. PubMed ID: 38922297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNAM1 and 2B4 Costimulatory Domains Enhance the Cytotoxicity of Anti-GPC3 Chimeric Antigen Receptor-Modified Natural Killer Cells Against Hepatocellular Cancer Cells in vitro.
    Huang Y; Zeng J; Liu T; Xu Q; Song X; Zeng J
    Cancer Manag Res; 2020; 12():3247-3255. PubMed ID: 32440221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.
    Yu M; Luo H; Fan M; Wu X; Shi B; Di S; Liu Y; Pan Z; Jiang H; Li Z
    Mol Ther; 2018 Feb; 26(2):366-378. PubMed ID: 29339014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.
    Chen C; Li K; Jiang H; Song F; Gao H; Pan X; Shi B; Bi Y; Wang H; Wang H; Li Z
    Cancer Immunol Immunother; 2017 Apr; 66(4):475-489. PubMed ID: 28035433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiotherapy enhances the anti-tumor effect of CAR-NK cells for hepatocellular carcinoma.
    Lin X; Liu Z; Dong X; Wang K; Sun Y; Zhang H; Wang F; Chen Y; Ling J; Guo Y; Xiang H; Xie Q; Zhang Y; Guo Z; Sugimura R; Xie G
    J Transl Med; 2024 Oct; 22(1):929. PubMed ID: 39396988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy.
    Lu LL; Xiao SX; Lin ZY; Bai JJ; Li W; Song ZQ; Zhou YH; Lu B; Wu WZ
    Cell Biol Toxicol; 2023 Dec; 39(6):3101-3119. PubMed ID: 37853185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report.
    Sun H; Xing C; Jiang S; Yu K; Dai S; Kong H; Jin Y; Shan Y; Yang W; Wang Z; Xiao J; Wang H; Wang W; Li Z; Shi K
    Front Immunol; 2022; 13():963031. PubMed ID: 36059488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma.
    Sun L; Gao F; Gao Z; Ao L; Li N; Ma S; Jia M; Li N; Lu P; Sun B; Ho M; Jia S; Ding T; Gao W
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33833049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble programmed death ligand-1-induced immunosuppressive effects on chimeric antigen receptor-natural killer cells targeting Glypican-3 in hepatocellular carcinoma.
    Chen L; Liu S; Adah D; Sun Q; Liang Z; Ho M; Sun B
    Immunology; 2023 Jun; 169(2):204-218. PubMed ID: 36640111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Construction and function of Glypican-3-targeted fourth-generation chimeric antigen receptor T cells (secreting IL-7 and CCL19)].
    Huang W; Liu Y; Hu Y; Gao J
    Sheng Wu Gong Cheng Xue Bao; 2020 May; 36(5):979-991. PubMed ID: 32567281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma.
    Wang H; Wang X; Ye X; Ju Y; Cao N; Wang S; Cai J
    BMC Cancer; 2022 Jul; 22(1):814. PubMed ID: 35879685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GPC3-targeted CAR-T cells secreting B7H3-targeted BiTE exhibit potent cytotoxicity activity against hepatocellular carcinoma cell in the in vitro assay.
    Cao G; Zhang G; Liu M; Liu J; Wang Q; Zhu L; Wan X
    Biochem Biophys Rep; 2022 Sep; 31():101324. PubMed ID: 36032401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of GPC3-specific chimeric antigen receptor structure and its effect on killing hepatocellular carcinoma cells.
    Zhao J; Lin L; Luo Y; Cai Q; Jiang X; Liao C; Wei H
    Bioengineered; 2021 Dec; 12(1):3674-3683. PubMed ID: 34261411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma.
    Liu X; Gao F; Jiang L; Jia M; Ao L; Lu M; Gou L; Ho M; Jia S; Chen F; Gao W
    J Transl Med; 2020 Aug; 18(1):295. PubMed ID: 32746924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma.
    Guo X; Jiang H; Shi B; Zhou M; Zhang H; Shi Z; Du G; Luo H; Wu X; Wang Y; Sun R; Li Z
    Front Pharmacol; 2018; 9():1118. PubMed ID: 30327605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GPC3-targeted CAR-M cells exhibit potent antitumor activity against hepatocellular carcinoma.
    Guan L; Wu S; Zhu Q; He X; Li X; Song G; Zhang L; Yin X
    Biochem Biophys Rep; 2024 Sep; 39():101741. PubMed ID: 38881757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
    Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
    Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice.
    Li D; Li N; Zhang YF; Fu H; Feng M; Schneider D; Su L; Wu X; Zhou J; Mackay S; Kramer J; Duan Z; Yang H; Kolluri A; Hummer AM; Torres MB; Zhu H; Hall MD; Luo X; Chen J; Wang Q; Abate-Daga D; Dropulic B; Hewitt SM; Orentas RJ; Greten TF; Ho M
    Gastroenterology; 2020 Jun; 158(8):2250-2265.e20. PubMed ID: 32060001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein.
    Pan Z; Di S; Shi B; Jiang H; Shi Z; Liu Y; Wang Y; Luo H; Yu M; Wu X; Li Z
    Cancer Immunol Immunother; 2018 Oct; 67(10):1621-1634. PubMed ID: 30078052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma.
    Batra SA; Rathi P; Guo L; Courtney AN; Fleurence J; Balzeau J; Shaik RS; Nguyen TP; Wu MF; Bulsara S; Mamonkin M; Metelitsa LS; Heczey A
    Cancer Immunol Res; 2020 Mar; 8(3):309-320. PubMed ID: 31953246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.